TSPT Transcept Pharmaceuticals, Inc. featured news, full reports, and detailed charts
Transcept Pharmaceuticals, Inc. (TSPT) Wrap Up:
We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Our product portfolio features two clinical-stage oncology product candidates with worldwide rights, Asentar™ and AQ4N, each of which is a potential treatment for certain types of cancer. In May 2007, we signed an exclusive worldwide License, Development and Commercialization Agreement, or the Collaboration Agreement, with Schering Corporation, a wholly-owned subsidiary of Schering-Plough Corporation (“Schering”), for the development and commercialization of Asentar™ (the “Collaboration Agreement”) in androgen-independent prostate cancer, or AIPC, earlier stages of prostate cancer, and in other types of cancers, including pancreatic cancer. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f17%2f0001193125-08-058927.html#FIS_BUSINESS"Transcept Pharmaceuticals, Inc. (TSPT:NASDAQ)
Snapshot of Transcept Pharmaceuticals, Inc. (TSPT)
|
OPEN
$5.35
|
PREVIOUS CLOSE
$5.43
|
|
|
DAY HIGH
$5.40
|
DAY LOW
$5.30
|
|
|
52 WEEK HIGH
10/19/09 - $15.40
|
52 WEEK LOW
02/2/09 - $1.11
|
|
|
MARKET CAP
71.1M
|
AVERAGE VOLUME 3 mo
130.3K
|
|
|
DILUTED EPS TTM
$-2.60
|
SHARES OUTSTANDING
13.4M
|
|
|
TSPT Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
TSPT Top Compensated Officers
Executives, Board Directors
Key developments for Transcept Pharmaceuticals, Inc. (TSPT)
Transcept Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net loss of approximately $3.8 million or $0.29 per basic and diluted share compared to a net loss of approximately $4.3 million or $10.08 per basic and diluted share for the quarter ended September 30, 2008. The company recorded $2.08 million of revenue, related to recognition of a portion of the $25 million non-refundable license fee received from Purdue in connection with the signing of collaboration agreement. Loss from operations was $3.9 million compared to $4.6 million for the same period of last year. For the nine months, the company reported net loss of approximately $19.5 million or $1.65 per basic and diluted share compared to a net loss of approximately $13.8 million or $35.93 per basic and diluted share for the nine months ended September 30, 2008. Revenue was $2.08 million related to recognition of a portion of the $25 million non-refundable license fee received from Purdue in connection with the signing of collaboration agreement, compared to no revenue for the nine months ended September 30, 2008. Loss from operations was $19.8 million compared to $14.2 million for the same period of last year.
Transcept Pharmaceuticals, Inc. - Conference Presentation Calls
Transcept Pharmaceuticals, Inc., Q3 2009 Earnings Call, Nov 12 2009
TSPT Competitors
| Company | Last | Change | |
| No competitor information is available for TSPT. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | TSPT | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 33.6x |
|
| Price/Book | 1.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
TSPT |
||
TSPT transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||